Budget Impact Analysis of Niraparib and Olaparub As Maintenance Therapy for Platinum Sensitive, Recurrent Ovarian Cancer In The US

Value in Health ◽

10.1016/j.jval.2018.04.132 ◽

2018 ◽

Vol 21 ◽

pp. S22

Author(s):

L Wu ◽

L Zhong

Keyword(s):

Ovarian Cancer ◽

Maintenance Therapy ◽

Impact Analysis ◽

Budget Impact ◽

Recurrent Ovarian Cancer ◽

Budget Impact Analysis ◽

Platinum Sensitive ◽

Download Full-text

Budget impact analysis of niraparib and olaparib for maintenance treatment of platinum-sensitive, recurrent ovarian cancer in the US

Journal of Medical Economics ◽

10.1080/13696998.2018.1557199 ◽

2019 ◽

Vol 22 (2) ◽

pp. 187-195 ◽

Author(s):

Lei Wu ◽

Lixian Zhong

Keyword(s):

Ovarian Cancer ◽

Maintenance Treatment ◽

Impact Analysis ◽

Budget Impact ◽

Recurrent Ovarian Cancer ◽

Budget Impact Analysis ◽

Platinum Sensitive ◽

Download Full-text

Budget Impact Analysis For Olaparib Maintenance Therapy for Brca-Mutated Platinum Sensitive Recurrent Ovarian Cancer in Costa Rica

Value in Health ◽

10.1016/j.jval.2018.04.127 ◽

2018 ◽

Vol 21 ◽

pp. S21

Author(s):

FG Torres Toala ◽

J Solorzano ◽

J Baldi ◽

D Landaverde ◽

I González

Keyword(s):

Ovarian Cancer ◽

Maintenance Therapy ◽

Impact Analysis ◽

Budget Impact ◽

Recurrent Ovarian Cancer ◽

Budget Impact Analysis ◽

Platinum Sensitive

Download Full-text

Budget impact analysis of niraparib for first-line maintenance therapy in advanced ovarian cancer from a US payer perspective

Journal of Managed Care & Specialty Pharmacy ◽

10.18553/jmcp.2021.27.10.1377 ◽

2021 ◽

Vol 27 (10) ◽

pp. 1377-1387

Author(s):

Jinan Liu ◽

Carol Hawkes ◽

Lydia Walder ◽

Chloe Spalding ◽

Karin Travers ◽

...

Keyword(s):

Ovarian Cancer ◽

Maintenance Therapy ◽

Impact Analysis ◽

Budget Impact ◽

Advanced Ovarian Cancer ◽

Budget Impact Analysis ◽

Payer Perspective

Download Full-text

Budget Impact for Olaparib Maintenance Therapy for Brca-Mutated Platinum Sensitive Recurrent Ovarian Cancer in Panama

Value in Health ◽

10.1016/j.jval.2018.04.134 ◽

2018 ◽

Vol 21 ◽

pp. S22

Author(s):

FG Torres Toala ◽

J Solorzano ◽

J Baldi ◽

O Castillo-Fernandez

Keyword(s):

Ovarian Cancer ◽

Maintenance Therapy ◽

Budget Impact ◽

Recurrent Ovarian Cancer ◽

Platinum Sensitive

Download Full-text

Budget Impact for Olaparib Maintenance Therapy for Brca-Mutated Platinum Sensitive Recurrent Ovarian Cancer in Peru

Value in Health ◽

10.1016/j.jval.2018.04.133 ◽

2018 ◽

Vol 21 ◽

pp. S22

Author(s):

FG Torres Toala ◽

J Solorzano ◽

J Baldi

Keyword(s):

Ovarian Cancer ◽

Maintenance Therapy ◽

Budget Impact ◽

Recurrent Ovarian Cancer ◽

Platinum Sensitive

Download Full-text

Niraparib maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer and a time-to-progression after penultimate platinum-based chemotherapy of 6-12 or >12 months: a subgroup analysis of the phase III NORA trial

Gynecologic Oncology ◽

10.1016/s0090-8258(21)00681-8 ◽

2021 ◽

Vol 162 ◽

pp. S18

Author(s):

Qidan Huang ◽

Xiaohua Wu ◽

Jianqing Zhu ◽

Danqing Wang ◽

Jiaxin Yang ◽

...

Keyword(s):

Ovarian Cancer ◽

Maintenance Therapy ◽

Subgroup Analysis ◽

Recurrent Ovarian Cancer ◽

Phase Iii ◽

Time To Progression ◽

Platinum Sensitive ◽

Platinum Based Chemotherapy

Download Full-text

A single-arm, phase II study of niraparib and bevacizumab maintenance therapy in platinum-sensitive, recurrent ovarian cancer patients previously treated with a PARP inhibitor: Korean Gynecologic Oncology Group (KGOG 3056)/NIRVANA-R trial

Journal of Gynecologic Oncology ◽

10.3802/jgo.2022.33.e12 ◽

2022 ◽

Vol 33 ◽

Author(s):

Junsik Park ◽

Myong Cheol Lim ◽

Jae-Kwan Lee ◽

Dae Hoon Jeong ◽

Se Ik Kim ◽

...

Keyword(s):

Ovarian Cancer ◽

Maintenance Therapy ◽

Phase Ii Study ◽

Parp Inhibitor ◽

Gynecologic Oncology ◽

Recurrent Ovarian Cancer ◽

Gynecologic Oncology Group ◽

Oncology Group ◽

Platinum Sensitive ◽

Previously Treated

Download Full-text

Alemtuzumab Budget Impact Analysis in Relapsing-Remitting Multiple Sclerosis in the US

Value in Health ◽

10.1016/j.jval.2015.03.1637 ◽

2015 ◽

Vol 18 (3) ◽

pp. A280

Author(s):

C. Celestin ◽

T. Wandstrat ◽

C.I. Coleman

Keyword(s):

Multiple Sclerosis ◽

Impact Analysis ◽

Budget Impact ◽

Budget Impact Analysis ◽

Relapsing Remitting ◽

The Us ◽

Remitting Multiple Sclerosis ◽

Relapsing Remitting Multiple Sclerosis

Download Full-text

Real world occurrence of top three clinical-trial reported adverse events of PARP inhibitor niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer, a national retrospective observational study of a 200 mg/day starting-dose cohort

Annals of Oncology ◽

10.1093/annonc/mdy285.193 ◽

2018 ◽

Vol 29 ◽

pp. viii351-viii352

Author(s):

J.R. Gallagher ◽

K.J. Heap ◽

S. Carroll

Keyword(s):

Ovarian Cancer ◽

Clinical Trial ◽

Adverse Events ◽

Observational Study ◽

Maintenance Therapy ◽

Parp Inhibitor ◽

Recurrent Ovarian Cancer ◽

Dose Cohort ◽

Platinum Sensitive ◽

Download Full-text

PARP inhibitor maintenance therapy for patients with platinum-sensitive recurrent ovarian cancer: A cost-effectiveness analysis

Gynecologic Oncology ◽

10.1016/j.ygyno.2015.08.013 ◽

2015 ◽

Vol 139 (1) ◽

pp. 59-62 ◽

Author(s):

Haller J. Smith ◽

Christen L. Walters Haygood ◽

Rebecca C. Arend ◽

Charles A. Leath ◽

J. Michael Straughn

Keyword(s):

Ovarian Cancer ◽

Cost Effectiveness ◽

Maintenance Therapy ◽

Parp Inhibitor ◽

Recurrent Ovarian Cancer ◽

Cost Effectiveness Analysis ◽

Platinum Sensitive ◽

Effectiveness Analysis

Download Full-text